Results 171 to 180 of about 3,296 (215)
Some of the next articles are maybe not open access.
New Approaches to Cancer Chemoprevention With Difluoromethylornithine and Selenite
JNCI Journal of the National Cancer Institute, 1989New approaches to enhancing D,L-alpha-difluoromethylornithine (DFMO) inhibition of DMBA-induced mammary tumorigenesis were investigated. It is reasoned that perturbation of a second regulatory element in polyamine biosynthesis, i.e., the generation of propylamine groups from S-adenosylmethionine (AdoMet), would potentiate the effectiveness of DFMO ...
C, Ip, H J, Thompson
openaire +2 more sources
A Trypanosoma brucei mutant resistant to α-difluoromethylornithine
Molecular and Biochemical Parasitology, 1987Procyclic Trypanosoma brucei brucei strain 366D is susceptible to DL-alpha-difluoromethylornithine (DFMO) with an in vitro ED50 value of 225 microM. A mutant of the procyclic strain resistant to 20 mM of DFMO was isolated by serial in vitro passages of the organisms in increasing concentrations of the drug.
M A, Phillips, C C, Wang
openaire +2 more sources
An Animal Model of Hearing Loss From -Difluoromethylornithine
Archives of Otolaryngology - Head and Neck Surgery, 1989alpha-Difluoromethylornithine is a new antineoplastic and antiparasitic drug that inhibits the synthesis of polyamines. It causes a sensorineural hearing loss in humans. We have established an animal model for alpha-difluoromethylornithine-induced hearing loss.
C, Jansen +3 more
openaire +2 more sources
Alpha-Difluoromethylornithine Infusion and Cardiac Arrest
Annals of Internal Medicine, 1986Excerpt To the editor: Alpha-difluoromethylornithine is an investigational antiprotozoal agent used to treatPneumocystis cariniipneumonia in patients with the acquired immunodeficiency syndrome (AI...
RICK A. BARBARASH +2 more
openaire +1 more source
-Difluoromethylornithine Ototoxicity: Chemoprevention Clinical Trial Results
Archives of Otolaryngology - Head and Neck Surgery, 1997To determine the effects of low-dose oral eflornithine hydrochloride (difluoromethylornithine [DFMO]) administration on hearing and to identify factors that influence those effects.Combined data from 2 studies: a prospective, randomized phase 1 clinical trial of eflornithine (n = 26 subjects) and a prospective, randomized, placebo-controlled phase 2 ...
T R, Pasic, D, Heisey, R R, Love
openaire +2 more sources
Chemoprevention in prostate cancer: The role of difluoromethylornithine (DFMO)
Journal of Cellular Biochemistry, 1992The polyamines are normal cell constituents considered to have an important role in the regulation of proliferation and differentiation. DFMO is an irreversible, enzyme-activated, suicide inhibitor of ornithine decarboxylase (ODC), the enzyme responsible for the first and rate-limiting step in mammalian polyamine synthesis.
openaire +2 more sources
Phase I study of alpha-difluoromethylornithine and methyl-GAG
European Journal of Cancer and Clinical Oncology, 1986alpha-Difluoromethylornithine (DFMO) is a potent inhibitor of the synthesis of putrescine (pu) and spermidine (sd) in some benign and malignant tissues. Intracellular deprivation of pu and sd has been shown to induce an enhanced uptake of polyamine-analogs such as methyl-GAG (MGBG).
T A, Splinter, J C, Romijn
openaire +2 more sources
Effects of gastrin and difluoromethylornithine on growth of human colon cancer
Digestive Diseases and Sciences, 1993The effect of difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase activity, was evaluated in vivo and in vitro on the growth of a gastrin-sensitive human colon carcinoma (WiDr). In vivo, mice bearing the tumor treated with pentagastrin had larger tumors with higher ornithine decarboxylase activity and polyamine content (P ...
J P, Smith, S T, Kramer, L M, Demers
openaire +2 more sources
Effect of difluoromethylornithine on the LH surge and subsequent ovulation in the rat
Journal of Endocrinology, 1988ABSTRACT Female Wistar-derived rats with regular oestrous cycles were injected s.c. at 15.00 h on pro-oestrus with difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase. The drug (10–100 mg/rat) caused a dose-related reduction in the concentration of LH in plasma taken at 19.00 h (the time of the peak of the LH surge ...
S A, Nicholson +4 more
openaire +2 more sources
Phase I evaluation of intravenous difluoromethylornithine — a polyamine inhibitor
Investigational New Drugs, 1985Difluoromethylornithine (DFMO), a non-competitive inhibitor of ornithine decarboxylase (ODC), the rate limiting enzyme of the polyamine synthetic pathway was evaluated in a Phase I trial. Intravenous DFMO was given to twenty patients with refractory leukemia by continuous infusion in doses from 5.5 to 64 g/m2.
A M, Maddox +4 more
openaire +2 more sources